Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00471094 · ClinicalTrials.gov registry record · Phase 2
Safety and Efficacy of Ilaprazole 5, 20 and 40 mg QD and Lansoprazole 30 mg QD on Healing of Erosive Esophagitis
A Phase 2 study, sponsored by Takeda.
- Completed
- Registry status
- Phase 2
- Development phase
- 831
- Enrollment target
NCT00471094: Completed Phase 2 study, sponsored by Takeda.
NCT00471094 is a Phase 2 study that has completed, run by Takeda. The registered enrollment target is 831 participants, above the 133-participant average among 30,622 other Phase 2 trials with a reported enrollment target (525% higher). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT00471094, a Phase 2 study, has completed, sponsored by Takeda.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 831 participants
- Enrollment target
Study Summary
The purpose of this study is to assess the efficacy and safety of 8 weeks of daily treatment with Ilaprazole (5, 20 and 40 mg), once daily (QD), compared to lansoprazole 30 mg in healing subjects with endoscopically proven erosive esophagitis.
Interventions
- DRUG Lansoprazole
- DRUG Ilaprazole
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 831 participants |
| Start Date | 2007-05 |
| Est. Completion | 2007-10 |
| Phase | Phase 2 |
What the finished NCT00471094 record still lists
NCT00471094 is an interventional study that assigns participants to a tested intervention. The registered 831 participants enrollment target is mid-sized for trials with a published cap, above the 133-participant average among 30,622 other Phase 2 trials with a reported enrollment target (525% higher).
The record links to 0 conditions, and to 2 interventions - of which Lansoprazole is the first listed.
NCT00471094 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT00471094 about?
NCT00471094 is a clinical study titled "Safety and Efficacy of Ilaprazole 5, 20 and 40 mg QD and Lansoprazole 30 mg QD on Healing of Erosive Esophagitis". The purpose of this study is to assess the efficacy and safety of 8 weeks of daily treatment with Ilaprazole (5, 20 and 40 mg), once daily (QD), compared to lansoprazole 30 mg in healing subjects with endoscopically proven erosive esophagitis.
What is the current status of trial NCT00471094?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 831 participants. The study started on 2007-05. Estimated completion is 2007-10.
What interventions are being tested in trial NCT00471094?
The interventions under investigation include: Lansoprazole (DRUG), Ilaprazole (DRUG).
Who is sponsoring clinical trial NCT00471094?
This trial is sponsored by Takeda, which has 408 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT00471094's enrollment target sits among peer trials
831 36th of 2000 higher than 1,965 of 2,000 other Phase 2 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 2 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT06910553 · 832 participants
IBD Pregnancy Registry
- NCT07089706 · 832 participants · Phase 4
A Study to Evaluate the Immunogenicity and Safety of mRNA-1283 COVID-19 Variant-containing Formulations
- NCT05067283 · 830 participants · Phase 1
A Study of Calderasib (MK-1084) in KRAS Mutant Advanced Solid Tumors (MK-1084-001)
- NCT06592924 · 830 participants · Phase 3
Docetaxel to Androgen Receptor Pathway Inhibitors in Patients With Metastatic Castration Sensitive Prostate Cancer and Suboptimal PSA Response
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia